Health insurance and diversity of treatment: a policy mix perspective
David Bardey (),
Bruno Jullien () and
Documentos CEDE from Universidad de los Andes - CEDE
We determine the optimal health policy mix when the average utility of patients in-creases with the supply of drugs available in a therapeutic class. Health risk coverage rely on two instruments, copayment and reference pricing, that affect the supported risk composed by health expenses and diversity of treatment. For a fixed supply of drugs, the reference pricing policy aims at minimizing expenses in which case, the equilibrium price of drugs is independent of the copayment rate. However, with endogenous supply of drugs, diversity of treatment may susbtitute for insurance so that the reference pricing may depart from maximal cost-containement to promote entry. We then analyse the determinents of the optimal policy. While an increase in risk aversion or in the side effect loss increases diversity and decreases the copayment rate, an increase in entry cost both decreases diversity and the copayment rate.
Keywords: Health Insurance; Drugs´Price Regulation; Diversity of Treatments. (search for similar items in EconPapers)
JEL-codes: I18 L11 L15 L51 (search for similar items in EconPapers)
New Economics Papers: this item is included in nep-hea and nep-ias
References: Add references at CitEc
Citations: View citations in EconPapers (1) Track citations by RSS feed
Downloads: (external link)
Working Paper: Health Insurance and Diversity of Treatment: A Policy Mix Perspective (2013)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:col:000089:010549
Access Statistics for this paper
More papers in Documentos CEDE from Universidad de los Andes - CEDE
Bibliographic data for series maintained by Universidad De Los Andes-Cede ().